Skip to main content
Health & Medicine

Efficacy and safety of garetosmab, an activin A-blocking antibody, in fibrodysplasia ossificans progressiva (OPTIMA): a randomised, double-blind, placebo-controlled, phase 3 trial.

| Source: Lancet (London, England)

Fibrodysplasia ossificans progressiva (FOP) is an ultrarare genetic disorder resulting in progressive heterotopic ossification of ligaments, tendons, and muscles, leading to disability and early mortality. FOP is caused by heterozygous gain-of-function mutations in the activin receptor type 1A, allowing this receptor to be aberrantly activated by activin A (ActA), which normally inhibits this receptor, thus driving heterotopic bone formation. In preclinical models and an earlier phase 2 trial (L

Fibrodysplasia ossificans progressiva (FOP) is an ultrarare genetic disorder resulting in progressive heterotopic ossification of ligaments, tendons, and muscles, leading to disability and early mortality. FOP is caused by heterozygous gain-of-function mutations in the activin receptor type 1A, allowing this receptor to be aberrantly activated by activin A (ActA), which normally inhibits this receptor, thus driving heterotopic bone formation. In preclinical models and an earlier phase 2 trial (LUMINA-1) in FOP, an antibody blocking ActA (garetosmab) prevented heterotopic ossification. We aimed to evaluate the efficacy and safety of garetosmab in adults living with FOP. OPTIMA is a randomised, double-blind, placebo-controlled, phase 3 trial conducted at 18 study sites across 16 countries and regions. Participants aged 18 years or older with FOP were randomly assigned (1:1:1) to monthly intravenous placebo, garetosmab 3 mg/kg, or garetosmab 10 mg/kg. Randomisation was stratified by baseline Cumulative Analogue Joint Involvement Scale score and previous participation in the LUMINA-1 study. The primary efficacy and safety endpoints were total number of new heterotopic bone lesions at week 56 and treatment-emergent adverse events of special interest (AESIs) through week 56, analysed in all randomised participants who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov (NCT05394116); the trial is active (completed primary endpoint) but not recruiting participants. Between Nov 21, 2022, and July 4, 2024, 63 participants were enrolled and randomly assigned (placebo, n=21; garetosmab 3 mg/kg, n=19; garetosmab 10 mg/kg, n=23). The mean age was 26·6 years (SD 6·8); 38 (60%) participants were female and 25 (40%) male. 62 participants completed 56 weeks of treatment; one participant in the placebo group discontinued at 53 weeks. The total number of new heterotopic bone lesions was significantly lower with garetosmab: there were 19 lesions with placebo versus one lesion with garetosmab 3 mg/kg (rate ratio vs placebo: 0·06 [95% CI 0·00-0·73]; p=0·027) and two lesions with garetosmab 10 mg/kg (rate ratio vs placebo: 0·10 [0·01-0·76]; p=0·026). Treatment-emergent AESIs occurred in one (5%) of 21 participants receiving placebo, zero of 19 receiving garetosmab 3 mg/kg, and four (17%) of 23 receiving garetosmab 10 mg/kg; all were considered treatment-related. No deaths occurred. Garetosmab substantially reduced the number of new heterotopic bone lesions, providing robust evidence of its potential to be an efficacious and generally well tolerated disease-modifying therapy for FOP. Regeneron Pharmaceuticals.

Read the original source →

Related Stories

Health & Medicine

Homeostatic control of stem cell activity during intestinal regeneration.

Stem cells proliferate rapidly to maintain tissue turnover during regeneration, yet the mechanisms preventing hyperproliferation remain unclear. Here, we identified nuclear factor Y (NF-Y) as a transcriptional repressor that maintains intestinal stem cell (ISC) quiescence. NF-Y restricts ISC proliferation by occupying the promoters of epidermal growth factor receptor (EGFR) signaling components, including Egfr , Mkp3 , Raf , Ras , and pnt , through regulation dependent on the histone acetyltrans

Continue reading
Health & Medicine

Spatial transcriptomics reveals organizational properties of the mouse spinal cord and alterations in neuropathic pain.

The spinal cord integrates diverse somatosensory inputs and executes motor outputs through anatomically and functionally distinct circuits. Here, we employed spatially resolved single-cell transcriptomic profiling of the adult mouse spinal cord to gain insights into the organizational logic of the spinal cord. Our results reveal distinct spatial and laminar distributions of neuronal subtypes, including axial level and sex-specific differences. Many neuronal subtypes exhibit lamina-specific somat

Continue reading
Health & Medicine

Acute degradation of Pumilio proteins reveals a biphasic posttranscriptional regulatory hierarchy in embryonic stem cell fate decision.

Posttranscriptional regulation is critical for mammalian embryogenesis yet has been underexplored. We previously showed that RNA-binding Pumilio proteins (Pum1/2) are essential for early mouse embryogenesis and embryonic stem cell (ESC) functions. Here, using acute protein degradation systems combined with time-resolved RNA sequencing and enhanced crosslinking and immunoprecipitation, we delineate a two-phase regulatory hierarchy modulated by Pum1/2 in mouse ESCs. The first phase, occurring with

Continue reading
Health & Medicine

Elastic interactions of mechanically polarizable cells.

Cells mechanically interact through the deformations they generate in their surrounding extracellular matrix. We present an analytical theory of the elastic interactions between cells that actively adapt their forces in response to local deformations of their environment. Cells are represented as localized contractile force generators, modeled as polarizable point force dipoles, whose adaptive forces are determined self-consistently with those of surrounding cells. Analysis of the associated ela

Continue reading
Health & Medicine

ChREBP drives diabetic kidney disease, and its inhibition confers renal protection.

Chronic kidney disease (CKD) represents a major medical burden. Diabetic kidney disease (DKD) is a leading cause of CKD, but intracellular pathways that can be pharmacologically targeted are poorly defined. Using transcriptome screening of DKD model mice we found that a carbohydrate-responsive element-binding protein (ChREBP)-dependent transcriptional cascade is markedly up-regulated in diabetic kidneys. Genetic ablation of ChREBP in diabetic mice ameliorated DKD, establishing ChREBP as a potent

Continue reading